You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

St.Paul, Minnesota

  • Heart Failure


The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the EASYTRAK 4 STEERABLE LV lead.

Study summary:

This is a prospective, multi-center clinical study is to evaluate the safety and effectiveness of the EASYTRAK 4 STEERABLE LV lead.


Inclusion Criteria: - Must receive a commercially available Guidant CRT-P or CRT-D device - Creatinine < 2.5 mg/dL obtained no more than two weeks prior to enrollment - Age 18 or above, or of legal age to give informed consent specific to state and national law - Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigation center and at the intervals defined by this protocol - Geographically stable residents who are available for follow-up Exclusion Criteria: - Have a known hypersensitivity to a 1.0 mg (0.5 mg per electrode) nominal dose of dexamethasone acetate - Have or had previous cardiac resynchronization therapy, a coronary venous pace/sense lead or attempted LV lead placement - Have pre-existing cardioversion/defibrillation leads or right ventricular pacing leads other than those specified in the investigational plan (unless the investigator intends to replace them with permitted cardioversion/defibrillation leads) - Currently requiring dialysis - Have had a myocardial infarct, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment - Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis) - Documented life expectancy of less than six months or expected to undergo heart transplant within the next six months - Enrolled or participating in any concurrent study, including drug investigations, without Guidant written approval, that may confound the results of this study - Have a pre-existing unipolar pacemaker that will not be explanted/abandoned - Have a mechanical tricuspid heart valve - Women who are pregnant or plan to become pregnant Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment.



Primary Contact:

Principal Investigator
Stephen Mester, MD
Tampa General Hospital

Backup Contact:


Location Contact:

St.Paul, Minnesota
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.